Work

From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?

Year: 2014

Type: review

Abstract: AD (Alzheimer's disease) is the most prevalent form of dementia in the aged population. Definitive diagnosis of AD is based on the presence of senile plaques and neurofibrillary tangles that are identified in post-mortem brain specimens. A third pathological component is inflammation. AD results from multiple genetic and environmental risk factors. Among other factors, epidemiological studies report beneficial effects of caffeine, a non-selective antagonist of adenosine receptors. In the present review, we discuss the impact of caffeine and the adenosinergic system in AD pathology as well as consequences in terms of pathology and therapeutics.

Source: Biochemical Society Transactions

DOI: 10.1042/bst20130229

Authors: Vanessa Flaten, Cyril Laurent, Joana E. Coelho, Ursula Sandau, Vânia L. Batalha, Sylvie Burnouf, Malika Hamdane, Sandrine Humez, Detlev Boison, Luísa V. Lopes, Luc Buée, David Blum

Institutions: Inserm, Centre de Recherche Jean Pierre Aubert, Université Lille Nord de France, University of Lisbon, Instituto de Medicina Molecular João Lobo Antunes, Legacy Health, Max Planck Institute for Biology of Ageing, Centre Hospitalier Universitaire de Lille

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institute of Mental Health, National Institute of Neurological Disorders and Stroke

Awards: Adenosine kinase antisense gene therapy for temporal lobe epilepsy., G2880307867, Astrocyte dysfunction in epileptogenesis: the role of adenosine, Glycine augmentation therapy for the treatment of epilepsy, Adenosine and schizophrenia: mechanisms and therapies, G59410889, G6131600684, Ketogenic Diet and Adenosine: Epigenetics and Antiepileptogenesis

OpenAlex ID: W2102878383

FWCI: 0.509

Cites: 110

Cited by: 51

Related to: 10